Efficacy of daclatasvir and asunaprevir for viral hepatitis С in two donor lung recipients

Abstract

Aim. To estimate efficacy and safety of direct antiviral drugs for hepatitis C treatment in donor lung recipients. Key points. The first cases in Russian literature and one of the first-ever cases of hepatitis C treatment by direct antiviral agents in lung transplant recipients are presented. Combined therapy by asunaprevir and daclatasvir for 24 weeks resulted in sustained virologic response. No significant adverse effects on drug to drug interactions, except for mild and controllable alteration of tacrolimus blood level, were noted. Conclusion. Daclatasvir and asunaprevir combination is effective and safe treatment mode for hepatitis C in donor lung recipients

Keywords

• противовирусные препараты
• гепатит с
• трансплантация легких
• даклатасвир
• асунапревир